[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650088":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":42,"responsibleParty":64,"collaborators":36,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":36,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":36,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":36,"overallStatus":45,"whyStopped":36,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Aswan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical 5-Fluorouracil Group","ACTIVE_COMPARATOR","About 20 cases suffering from Focal Vitiligo will receive 6 sessions of fractional Er:YAG laser at two-week intervals. Starting \\[immediately \\] after each laser session, patients will apply topical 5-fluorouracil (5% cream) once daily for two weeks. This 14-day topical application cycle will be repeated following each of the 6 laser sessions.",[13],"Drug: Tyrosine",{"label":15,"type":10,"description":16,"interventionNames":17},"L-tyrosine Cream Group","About 20 cases suffering from Focal Vitiligo will receive 6 sessions of fractional Er:YAG laser at two-week intervals. Starting \\[immediately \\] after each laser session, patients will apply topical L-tyrosine (2% cream) twice daily for two weeks. This continuous application will be maintained between laser sessions and after the final session.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Tyrosine","to evaluate and compare the therapeutic effects of topical tyrosine and topical( 5-FU) combined with fractional erbium:YAG laser in the treatment of focal vitiligo.",[15,9],[25],"Topical 5-Fluorouracil",[27],{"name":28,"affiliation":29,"role":30},"Moustafa Adam Ali El Taieb, Professor","Dermatology, Venereology and Andrology, Faculty of Medicine, Aswan University","STUDY_CHAIR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Yasmin Mahdy Mohamed Ahmed, MSC","CONTACT","+201126607448",null,"yasmin17041133@aswu.edu.eg",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Moustafa Adam Ali El Taieb, professor","+201092991101","moustafa.eltaib@aswu.edu.eg",[43],{"facility":44,"status":45,"city":46,"state":36,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Aswan University Hospital","RECRUITING","Aswān","Egypt","EG",{"type":50,"coordinates":51},"Point",[52,53],32.89942,24.09082,{"lat":53,"lon":52},[56,60],{"name":57,"role":34,"phone":58,"phoneExt":36,"email":59},"Mahmoud Ahmed Ali, Lecturer","+201002364902","mahmoudali@aswu.edu.eg",{"name":61,"role":34,"phone":62,"phoneExt":36,"email":63},"Mohamed Amer Ahmed Abdellatif, Lecturer","+01060394083","mohammed.abdellatif@aswu.edu.eg",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Yasmin Mahdy Mohamed","Resident of Dermatology, Venereology and Andrology","100650088","early-phase-1-efficacy-of-topical-tyrosine-versus-topical-5-fluorouracil-with-fractional-erbium-yag-laser-100650088",false,"NCT07742982","Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser","Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser in Focal Vitiligo: A Randomised Clinical Trial","Inclusion Criteria:\n\n\\- Patients with focal vitiligo\n\nExclusion Criteria:\n\n* Pregnancy.\n* Lactation.\n* Patients with segmental vitiligo.\n* Patients with autoimmune disease including thyroiditis.\n* Patients with chronic systemic diseases,such as anemia ,diabetes mellitus, immunosuppression, or chronic infections.\n* Patients with active skin infections.","ALL","18 Years","60 Years",{"count":79,"type":80},40,"ESTIMATED","INTERVENTIONAL",[83],"EARLY_PHASE1","Vitiligo is an autoimmune disorder affecting the skin, specifically targeting pigment-producing melanocytes, leading to noticeable regions of depigmentation characterized by white spots.\n\nIt is a widely prevalent skin disorder globally, affecting males and females almost equally, although it is reported slightly more frequently in females. In more than 60% of patients, the disease begins before the age of 30 and It has an estimated prevalence of roughly 0.2-2% across various populations, with around 0.4% in the European-derived white (EUR) population.",[86],"Focal Vitiligo","2026-08-07",{"date":89,"type":90},"2026-08-11","ACTUAL",{"date":92,"type":90},"2026-06-01",{"date":94,"type":80},"2027-06-10",{"name":5,"class":6},1]